Francis Knuettel II - 10 Nov 2026 Form 4 Insider Report for OS Therapies Inc (OSTX)

Reporting relationship: Chief Financial Officer
Issuer ticker: OSTX
Reported as of: 10 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Nov 2026, 16:30:15 UTC
Prior SEC filing: 30 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Francis Knuettel II

Filing notes and source

Key filing fact

Francis Knuettel II filed Form 4 for OS Therapies Inc (OSTX) on 12 Nov 2026.

Key facts

This page summarizes Francis Knuettel II's Form 4 filing for OS Therapies Inc (OSTX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Nov 2026, 16:30.

Change

Previous filing in this sequence was filed on 30 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001433316 Primary reporting owner

Francis Knuettel II

Relationship: Chief Financial Officer
Address: C/O OS THERAPIES INCORPORATED, 115 PULLMAN CROSSING ROAD, SUITE 103, GRASONVILLE
Signature: /s/ Francis Knuettel II
Signature date: 12 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OSTX transaction

Common Stock

Award

Transaction value
Shares: +250,000
Change %
Price: $0.000000^*
Shares after: 250,000
Date: 10 Nov 2026
Ownership: Direct
Footnotes: F1

OSTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,000
Date: 10 Nov 2026
Ownership: By Lara Knuettel Revocable Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OSTX transaction Derivative

Stock options (right to buy)

Award

Transaction value
Shares: +750,000
Change %
Price: $0.000000^*
Shares after: 750,000
Date: 10 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 750,000
Exercise price: $0.8900
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On November 10, 2026 (the "Grant Date"), the reporting person was granted 250,000 restricted stock units ("RSUs") pursuant to the terms and conditions of a restricted stock unit award agreement and the issuer's amended and restated 2023 incentive compensation plan. Each RSU represents a contingent right to receive one share of the issuer's common stock upon vesting and settlement. 20% of the RSUs vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.

Footnote F2

The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Footnote F3

On the Grant Date, the reporting person was granted options to purchase 750,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan. 20% of these options vested on the Grant Date, and the remaining 80% vest in 12 equal quarterly installments on the last day of each calendar quarter, commencing December 31, 2026 and ending September 30, 2029, provided that the reporting person is serving as an employee of the issuer on each applicable vesting date.